. home.aspx



Cigna launches new benefits solution aimed at making gene therapy more affordable

September 06, 2019 / Paige Minemyer

Cigna is launching a new solution as part of its health services business aimed at mitigating the high cost of emerging gene therapy treatments.  The Embarc Benefit Protection platform brings together expertise on medical management, health services and specialty pharmacy from Express Scripts, eviCore, Accredo and CuraScript SD, Cigna announced. The model is designed to alleviate high cost-sharing for patients and also prevent shock claims for employers and plan sponsors. Health plans that adopt Embarc will pay a per-member, per-month fee to participate in a gene therapy network. Physicians will be required to submit prior authorization for the drugs, but once they’re approved a patient will not be charged a copay at the pharmacy counter.